Terazosin HCl Dihydrate

Terazosin HCl is a selective α1-adrenoceptor antagonist, used for treatment of symptoms of an enlarged prostate (BPH).

Terazosin HCl Dihydrate Chemical Structure

Terazosin HCl Dihydrate Chemical Structure

CAS No. 70024-40-7

Purity & Quality Control

Batch: S205901 DMSO]26 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.97%
99.97

Terazosin HCl Dihydrate Related Products

Biological Activity

Description Terazosin HCl is a selective α1-adrenoceptor antagonist, used for treatment of symptoms of an enlarged prostate (BPH).
Targets
α-adrenergic receptor [1]
In vitro
In vitro Terazosin results in a significant loss of cell viability, via induction of apoptosis in a dose-dependent manner in prostate cancer cells. Terazosin suppresses prostate growth potentially via α 1-adrenoceptor-independent actions gains further support from another study documenting that Doxazosin inhibits proliferation of human vascular smooth muscle cells independently of an antagonistic effect on α1-adrenoceptor. [1] Terazosin blocks HERG currents in Xenopus oocytes with IC50 of 113.2 mM, while Terazosin blocks HERG channel inhibition in human HEK 293 cells with IC50 of 17.7 mM. [2] Terazosin or genistein treatment inhibits the growth of DU-145 cells in a dose-dependent manner, whereas has no effect on normal prostate epithelial cells. Terazosin results in the genistein-induced arrest of DU-145 cells in G2/M phase being overridden and an increase in apoptotic cells, as evidenced by procaspase-3 activation and PARP cleavage. [3] Terazosin induces cytotoxicity in PC-3 and human benign prostatic cells with an IC50 of more than 100 mM. [4]
In Vivo
In vivo Terazosin significantly inhibits vascular endothelial growth factor induced angiogenesis in nude mice with an IC50 of 7.9 mM, showing that it has a more potent anti-angiogenic than cytotoxic effect. Terazosin also effectively inhibits vascular endothelial growth factor induced proliferation and tube formation in cultured human umbilical vein endothelial cells (IC50 9.9 and 6.8 mM, respectively). [4]
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04760860 Not yet recruiting
Dementia With Lewy Bodies
Qiang Zhang|University of Iowa
October 2024 Phase 1|Phase 2
NCT04551040 Active not recruiting
Healthy
University of Iowa|Michael J. Fox Foundation for Parkinson''s Research
March 26 2021 Phase 1
NCT04386317 Recruiting
REM Sleep Behavior Disorder|Pre-motor Parkinson''s Disease|Symptomatic Parkinson Disease
Cedars-Sinai Medical Center
November 1 2020 Phase 2
NCT00449683 Completed
Hyperhidrosis
Thomas Jefferson University|National Alliance for Research on Schizophrenia and Depression
March 2007 Phase 4
NCT00237510 Completed
Antidepressant Induced Excessive Sweating
Thomas Jefferson University
May 2005 Not Applicable
NCT02244333 Completed
Prostatic Hyperplasia
Boehringer Ingelheim
February 2004 --

Chemical Information & Solubility

Molecular Weight 459.92 Formula

C19H25N5O4.HCl.2H2O

CAS No. 70024-40-7 SDF Download Terazosin HCl Dihydrate SDF
Smiles COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC.O.O.Cl
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 26 mg/mL ( (56.53 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Water : Insoluble

Ethanol : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Terazosin HCl Dihydrate | Terazosin HCl Dihydrate ic50 | Terazosin HCl Dihydrate price | Terazosin HCl Dihydrate cost | Terazosin HCl Dihydrate solubility dmso | Terazosin HCl Dihydrate purchase | Terazosin HCl Dihydrate manufacturer | Terazosin HCl Dihydrate research buy | Terazosin HCl Dihydrate order | Terazosin HCl Dihydrate mouse | Terazosin HCl Dihydrate chemical structure | Terazosin HCl Dihydrate mw | Terazosin HCl Dihydrate molecular weight | Terazosin HCl Dihydrate datasheet | Terazosin HCl Dihydrate supplier | Terazosin HCl Dihydrate in vitro | Terazosin HCl Dihydrate cell line | Terazosin HCl Dihydrate concentration | Terazosin HCl Dihydrate nmr